Synedgen Research Results Demonstrate New Therapy for Cystic Fibrosis Patients

Share Article

Chitosan Derivative Dissolves Biofilms, Reduces Mucus Viscosity and Enhances the Antibacterial Power of Tobramycin

Synedgen, Inc. announces new research results demonstrating that its proprietary chitosan derivative, SYN01, effectively dissolves biofilms, reduces mucus viscosity, and maintains broad antibiotic activity against Pseudomonas aeruginosa, a common cause of lung infection associated with cystic fibrosis. Pseudomonas aeruginosa settles into the thick mucus trapped in cystic fibrosis (CF) patients’ airways, resulting in a chronic respiratory infection for approximately 60 percent of cystic fibrosis patients.

The Synedgen researchers measured the impact of SYN01 on multi-drug resistant bacterial isolates obtained from CF patient sputum samples at Seattle Children’s Hospital. The bacteria in CF patient sputum often develop resistance to antibiotics used over the course of their lifetimes, making the treatment of infections more and more challenging as the patient ages. When drug resistant P. aeruginosa biofilms were treated with SYN01, the bacterial counts decreased by as much as 4-logs (99.99%) within just a few hours.

Other experiments were designed to look at the effects of SYN01 mixed in low doses with Tobramycin, a commonly prescribed antibiotic for Pseudomonas aeruginosa infection. These experiments showed a remarkable 32-fold enhancement of the antibiotics effectiveness against the same bacteria. “Since SYN01 forms holes in the bacteria and causes them to leak, it is highly unlikely that these organisms will develop resistance against this new treatment”, stated Synedgen Senior Microbiologist and principal investigator Dr. Stacy Townsend.

Dr. Townsend also noted that, “these results not only show that SYN01 can safely and effectively dissolve biofilms and reduce the thickness of mucus secretions, but also improve the effectiveness of the current standard of antibiotic therapy. This research offers the potential for new treatment options to safely and effectively improve lung function and to prevent and treat infection.”

Cystic fibrosis causes the body to produce abnormally thick and sticky mucus, which builds up in the lungs, digestive tract, and other areas of the body, resulting in life-threatening lung infections, painful sinusitis and serious digestive problems. The Cystic Fibrosis Foundation estimates the disease effects 30,000 individuals in the United States, and 70,000 worldwide. Although life expectancy for cystic fibrosis patients has increased, patients remain at an increased risk for serious lung infections such as Pseudomonas aeruginosa.

“These results suggest that SYN01 has powerful synergistic interactions with commonly used antibiotics, and could extend their effectiveness in patients who have developed resistance,” notes Dr. William Wiesmann, Synedgen, CEO. “We see tremendous opportunity to extend the lifetime of use of standard of care antibiotics while also dissolving the thick secretions that destroy lung function.”

This research will be presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on September 20 in Chicago, IL, at the New Approaches to Gram-Negative Drug Discovery session. The poster, Novel Biopolymer SYN01 Potentiates Antibacterial Activity of Tobramycin, Dissolves P. aeruginosa Biofilms, and Reduces the Viscosity of Cystic Fibrosis Sputum, summarizes theses findings and demonstrates the potential impact of Syndegen’s chitosan derivative for improving therapeutic options in cystic fibrosis lung infections.

About Synedgen
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. This platform technology provides the foundation for preventing bacterial growth and disruption of biofilms in human and environmental applications. Product development is targeted to specifically address unmet needs for therapies that treat and prevent infections, primarily from bacteria that have developed resistance to traditional antibiotics.

Synedgen’s Corporate Headquarters and Research Laboratories are in Claremont CA; Synedgen’s Manufacturing Facility is in Honolulu HI. Additional information can be found at Synedgen’s web site at


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nicole Draghic
Synedgen Inc
(301) 428-9818 x250
Email >
Visit website